Curvac Unmodified Vaccines

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

The company has said that they're going to finish the trial, because this was all based on an interm analysis of a hundred and 34 cases in a massive forty thousand person trial. In rat and monkey studies at least, it does look to be far better at eliciting antibodies. I think there's some people taking victory laps for modified arene and that that strategy has ultimately prevailed.

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.

News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.